pamidronate has been researched along with cytarabine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| de la Fuente, J; Goldman, JM; Hatjiharissi, E; Meletis, J; Rahemtulla, A; Szydlo, R; Terpos, E; Viniou, N; Yataganas, X | 1 |
| He, R; Li, J; Liu, X; Pan, R; Wang, C | 1 |
1 review(s) available for pamidronate and cytarabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for pamidronate and cytarabine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Biomarkers, Tumor; Bone Neoplasms; C-Reactive Protein; Cytarabine; Dexamethasone; Diphosphonates; Female; Glycoproteins; Humans; Interleukin-6; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Osteoclasts; Osteogenesis; Osteoprotegerin; Pamidronate; Paraproteins; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reference Values; Sensitivity and Specificity; Tartrate-Resistant Acid Phosphatase; Vincristine | 2003 |
Prenylation-dependent Ras inhibition by pamidronate inhibits pediatric acute myeloid leukemia stem and differentiated cell growth and survival.
Topics: Anilides; Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzothiazoles; Bone Density Conservation Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Child; Cytarabine; Daunorubicin; Drug Repositioning; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Pamidronate; Phenylurea Compounds; Primary Cell Culture; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; ras Proteins | 2019 |